The deals are among the most politically significant announcements to date in the Trump administration's efforts to rein in high U.S. drug costs.

White House’s landmark deal with Novo Nordisk and Eli Lilly will cut costs from at least $1,000 to about $350

The deal also means Medicare will start covering obesity drugs for some patients for the first time beginning next year.